Fourth quarter 2023 revenues increased 1% to 3.43billionversusfourthquarter2022;excludingRonapreveTM(a)(b),revenuesincreased1413.12 billion versus full year 2022; excluding Ronapreve(a), revenues increased 12% Fourth quarter 2023 Dupixent® global net sales (recorded by Sanofi) increased 31% to 3.22billionversusfourthquarter2022;fullyear2023Dupixentglobalnetsalesincreased3311.59 billion versus 2022 Fourth quarter 2023 U.S. net sales f ...